Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has shared an update.
Clover Biopharmaceuticals has provided additional details on its settlement agreement with Gavi, the Vaccine Alliance, outlining a capped and structured schedule of semi-annual deferred payments and contingent success-based payments over a 12-year term. The company will make semi-annual payments up to a maximum of US$22 million and contingent payments up to US$36 million, with the total future obligations estimated between US$34.8 million and US$58 million, excluding an initial US$7 million already paid.
The payment obligations will be funded from internal resources and future operating and financing cash flows, with mechanisms linking payment levels to cash balances and actual revenues or equity financing proceeds to preserve liquidity. By replacing Gavi’s claim for repayment of US$224 million in advance purchase amounts with this capped framework, Clover reduces financial uncertainty, supports its ability to maintain operations and R&D activities, and enhances visibility for shareholders and potential investors regarding its long-term financial planning.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing vaccines and other biologic therapies. Operating through its subsidiaries, including Clover Pharmaceuticals (Hong Kong) Co., Limited, the group targets global markets with an emphasis on advancing its core pipeline and strategic research and development priorities.
Average Trading Volume: 4,595,543
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.7B
For detailed information about 2197 stock, go to TipRanks’ Stock Analysis page.